These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 1548513)
21. Platinum compounds in the treatment of advanced breast cancer. Martín M Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413 [TBL] [Abstract][Full Text] [Related]
23. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial. Markman M; Blessing JA; DeGeest K; Morgan M; Look KY; Herzog TJ; Rose PG Gynecol Oncol; 1999 Dec; 75(3):444-6. PubMed ID: 10600304 [TBL] [Abstract][Full Text] [Related]
24. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Ozols RF Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119 [TBL] [Abstract][Full Text] [Related]
25. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Deng HB; Adikari M; Parekh HK; Simpkins H Cancer Chemother Pharmacol; 2004 Oct; 54(4):301-7. PubMed ID: 15138708 [TBL] [Abstract][Full Text] [Related]
26. The future role of carboplatin. Ruckdeschel JC Semin Oncol; 1994 Oct; 21(5 Suppl 12):114-8. PubMed ID: 7992063 [TBL] [Abstract][Full Text] [Related]
31. Chemotherapy for advanced ovarian cancer: overview of randomized trials. Thigpen JT Semin Oncol; 2000 Jun; 27(3 Suppl 7):11-6. PubMed ID: 10952121 [TBL] [Abstract][Full Text] [Related]
32. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Gupta-Burt S; Shamkhani H; Reed E; Tarone RE; Allegra CJ; Pai LH; Poirier MC Cancer Epidemiol Biomarkers Prev; 1993; 2(3):229-34. PubMed ID: 8318875 [TBL] [Abstract][Full Text] [Related]
33. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities]. du Bois A; Lück HJ; Meerpohl HG Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970 [TBL] [Abstract][Full Text] [Related]
34. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. Francis P; Schneider J; Hann L; Balmaceda C; Barakat R; Phillips M; Hakes T J Clin Oncol; 1994 Nov; 12(11):2301-8. PubMed ID: 7964944 [TBL] [Abstract][Full Text] [Related]
36. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study. Lorusso V; Catino A; Leone B; Rabinovich M; Gargano G; Paradiso A; De Lena M J Clin Oncol; 1993 Oct; 11(10):1952-6. PubMed ID: 8410121 [TBL] [Abstract][Full Text] [Related]
37. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Neubauer H; Stefanova M; Solomayer E; Meisner C; Zwirner M; Wallwiener D; Fehm T Anticancer Res; 2008; 28(2A):949-55. PubMed ID: 18507041 [TBL] [Abstract][Full Text] [Related]
38. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel. Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790 [TBL] [Abstract][Full Text] [Related]
39. Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer. Markman M Semin Oncol; 1995 Jun; 22(3 Suppl 6):88-9. PubMed ID: 7597438 [TBL] [Abstract][Full Text] [Related]